Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks

Core Viewpoint - TScan Therapeutics, Inc. (TCRX) is experiencing significant selling pressure but is positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Stock Performance - TCRX has declined by 5.6% over the past four weeks, indicating a downward trend [1]. - The current Relative Strength Index (RSI) for TCRX is 25.67, suggesting that heavy selling may be exhausting itself [5]. Group 2: Analyst Sentiment - There is strong consensus among Wall Street analysts that TCRX will report better earnings than previously predicted, with a 0.9% increase in the consensus EPS estimate over the last 30 days [6]. - TCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [7]. Group 3: Technical Indicators - The RSI is a momentum oscillator that helps identify oversold conditions, typically when the reading falls below 30 [2]. - The RSI assists investors in spotting potential entry opportunities when a stock is undervalued due to unwarranted selling pressure [3].